[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].

Q3 Medicine
Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi
{"title":"[Polatuzumab vedotin in the treatment of relapsed or refractory DLBCL: a case report].","authors":"Daniele Contin, Roberto Sartori, Sara Berti, Alida Sartorello, Carlo Giovanni Doroldi","doi":"10.1701/4556.45580","DOIUrl":null,"url":null,"abstract":"<p><p>Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.</p>","PeriodicalId":20887,"journal":{"name":"Recenti progressi in medicina","volume":"116 9","pages":"530-535"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Recenti progressi in medicina","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1701/4556.45580","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Diffuse large B-cell lymphomas (DLBCLs) represent one of the most common and aggressive forms of non-Hodgkin lymphoma (NHL), characterized by rapid B-cell growth and a significantly high risk of relapse or refractoriness. The clinical course for these patients is long and complicated with a sometimes dismal prognosis, and the therapeutic approach must include effective and innovative chemotherapeutic treatments. The therapeutic strategies for DLBCLs in recent years has seen considerable pharmacological enrichment, including drug-conjugated antibodies such as polatuzumab vedotin. Indeed, this drug has demonstrated its efficacy even in the age-unfit elderly patient, providing a good safety and tolerability profile. Specifically, is described the case of an elderly patient with relapsed/refractory DLBCL with extra-nodal and bone disease presentation, treated second-line with polatuzumab vedotin in combination with rituximab and bendamustine. This combination resulted in a complete clinical and metabolic response while preserving excellent drug tolerance during treatment and improving the patient's quality of life.

[Polatuzumab vedotin治疗复发或难治性DLBCL: 1例报告]。
弥漫性大b细胞淋巴瘤(DLBCLs)是非霍奇金淋巴瘤(NHL)最常见和侵袭性的形式之一,其特点是b细胞生长迅速,复发或难治性风险高。这些患者的临床过程漫长而复杂,有时预后不佳,治疗方法必须包括有效和创新的化疗治疗。近年来,dlbcl的治疗策略已经有了相当大的药理学丰富,包括药物偶联抗体,如polatuzumab vedotin。事实上,这种药物即使在年龄不适合的老年患者中也证明了其有效性,提供了良好的安全性和耐受性。具体来说,描述了一例伴有淋巴结外和骨骼疾病表现的复发/难治性DLBCL老年患者,用polatuzumab vedotin联合利妥昔单抗和苯达莫司汀进行二线治疗。这种组合产生了完全的临床和代谢反应,同时在治疗期间保持了良好的药物耐受性,并改善了患者的生活质量。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Recenti progressi in medicina
Recenti progressi in medicina Medicine-Medicine (all)
CiteScore
0.90
自引率
0.00%
发文量
143
期刊介绍: Giunta ormai al sessantesimo anno, Recenti Progressi in Medicina continua a costituire un sicuro punto di riferimento ed uno strumento di lavoro fondamentale per l"ampliamento dell"orizzonte culturale del medico italiano. Recenti Progressi in Medicina è una rivista di medicina interna. Ciò significa il recupero di un"ottica globale e integrata, idonea ad evitare sia i particolarismi della informazione specialistica sia la frammentazione di quella generalista.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信